EcoDrugPlus

Ribosomal Protein Lateral Stalk Subunit P1

Ensembl ID : ENSCGOG00000010946
Gene Symbol: RPLP1
3 Cross references
386 Possible Orthologues:

Serum Amyloid P-Component-Like

Ensembl ID : ENSCGOG00000023323
Gene Symbol: LOC115021459
2 Cross references
410 Possible Orthologues:

Serum Amyloid P-Component-Like

Ensembl ID : ENSCGOG00000023314
Gene Symbol: LOC115021234
2 Cross references
404 Possible Orthologues:

Si:dkey-211g8.6

Ensembl ID : ENSCGOG00000016092
Gene Symbol: SI:DKEY-211G8.6
1 Cross references
319 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSCGOG00000007566
Gene Symbol: SIGMAR1
3 Cross references
205 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSCGOG00000020616
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha-Like

Ensembl ID : ENSCGOG00000010653
Gene Symbol: LOC115022123
3 Cross references
245 Possible Orthologues:

Sodium Channel Protein Type 5 Subunit Alpha-Like

Ensembl ID : ENSCGOG00000015489
Gene Symbol: LOC115005895
3 Cross references
260 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSCGOG00000003461
Gene Symbol: SCN4A
3 Cross references
187 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSCGOG00000016731
Gene Symbol: SCN8A
3 Cross references
218 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSCGOG00000020443
Gene Symbol: SCN8A
3 Cross references
219 Possible Orthologues:

Sodium- And Chloride-Dependent Gaba Transporter 1-Like

Ensembl ID : ENSCGOG00000015410
Gene Symbol: LOC115010450
3 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).